What You Need to Know About Semaglutide (Wegovy®): A Powerful Weight Loss Option

Semaglutide, commonly known as Wegovy®, is an FDA-approved treatment for chronic weight management in adults. It’s designed for individuals with specific health qualifications and can provide life-changing results when paired with a healthy lifestyle. Here’s what you should know:

Who Qualifies for Wegovy®?You may be a candidate for Wegovy® if:

• Your BMI (Body Mass Index) is 30 or higher (obesity), or

• Your BMI is 27 or higher (overweight) with at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol (FDA, 2021).

  
  

How Does It Work?Semaglutide mimics a hormone called GLP-1 that targets areas of the brain responsible for regulating appetite and food intake. It helps you feel full longer, reduces cravings, and promotes sustainable weight loss (Rubino et al., 2021).

What to Expect

• Administration: Wegovy® is a once-weekly injection you can administer at home.

• Results: In clinical trials, patients lost an average of 15% of their body weight over 68 weeks when combined with a reduced-calorie diet and increased physical activity (Wilding et al., 2021).

• Support: It’s not just about weight loss—Wegovy® can improve overall health, including reducing risks of obesity-related conditions.

  
  

Important Notes

• Prescription Only: Wegovy® requires a healthcare provider's approval. They will assess your medical history and ensure it’s the right option for you.

• Side Effects: Common side effects include nausea, diarrhea, or constipation, but these usually improve as your body adjusts (FDA, 2021).

  
  

Is It Right for You?If you’ve struggled with weight management and meet the qualifications, Wegovy® could be a game-changer. Speak with your healthcare provider about whether semaglutide is a good fit for your health goals.

Contact MEDIVA Health for a Consultation

Ready to explore your weight management options? MEDIVA Health is here to help! Visit www.medivahealth.com to book your consultation and take the first step toward a healthier you.

References

Food and Drug Administration (FDA). (2021). FDA approves Wegovy (semaglutide) injection for chronic weight management. Retrieved from www.fda.gov

Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., & Wadden, T. A. (2021). Effect of weekly semaglutide vs placebo on weight loss in adults with overweight or obesity: The STEP 1 clinical trial. Journal of the American Medical Association, 325(14), 1403-1413.

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., & Lingvay, I. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.